INTRODUCTION
============

Most postsurgical scars are considered esthetically and functionally acceptable. However, keloidal or hypertrophic scars can be symptomatic and might cause esthetic, psychological, and social distress.^[@R1]^ There is currently no definite, consensual measure that completely prevents postsurgical scarring. Therefore, many modalities are being explored, including laser treatment, to determine the safest and most efficacious method.^[@R2]^

The purpose of this review is to shed some light on the value of active scar mitigation by lasers, as compared to natural, spontaneous wound healing concerning final cosmesis of scars.

METHODS
=======

Search Strategy
---------------

Studies were identified through the search strategy by 2 independent reviewers.

A systematic National Institutes of Health--National Center for Biotechnology Information--PubMed search was conducted to identify relevant clinical articles that pertained to the use of lasers to mitigate postsurgical scars. Message-Subject-Headings were applied. The search algorithm used was (cicatrix OR cicatrix treatment OR scar OR scars) AND (laser OR laser treatment OR laser therapy OR fractional laser OR ablative fractional laser OR nonablative fractional laser OR dye laser OR diode laser) AND (prevention OR minimizing OR early intervention OR treatment outcome). Additional studies were acquired from review articles that appeared in the search. Only human trials that attributed pre- and posttreatment scores of scar severity based on a verified scar evaluation scale \[eg, Patient and Observer Scar Assessment Scale, Vancouver Scar Scale (VSS), Global Assessment Scale\], published in English, after January 1, 1995, were finally included.

The final studies that fit the inclusion criteria were identified using a 2-step process. First, the titles and abstracts of acquired articles were screened. Next, the complete text was reviewed. The inclusion and exclusion criteria are shown in Figure [1](#F1){ref-type="fig"}.
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Data Extraction
---------------

Standardized extraction of data was compiled and consolidated in a Microsoft Excel (Microsoft, Redmond, Wash., USA) spreadsheet. Acquired data included the name of the first author, year of publication, type of surgical wound, time of first treatment relative to operation date, device(s) and medications used, number of compared treatments, number of raters, number of patients subject to each treatment arm, parameters and settings on the device, number of treatments, time interval between treatments, study design, scar evaluation scale, statistical test used, *P* value, results, comments, and clarifications for future considerations.

Outcome Measures, Data Normalization, and Analysis
--------------------------------------------------

Different studies use different clinical assessment scores. To adequately assess the efficacy of the modalities, the final scaled scar appearance scores were realigned and normalized to a standard scale for unbiased comparison. This excluded studies that only reported improvement of scars and studies that did not adequately report their final results. Scales such as the VSS, the Global Assessment Scale, the Patient and Observer Scar Assessment Scale, Visual Analog Scale, and 4- and 5-level Likert scales were normalized to a standard 0--100 scale depicting 100 as healthy skin (= best esthetic outcome) and 0 as the worst possible scar (= worst esthetic outcome). Objective scar scores were defined as those determined by physicians, and subjective scar scores were those determined by patients.

The aligned scores were then compared: treatment versus control to calculate standard score, or *z* score, as it pertains to a single measurement, whereas standard mean difference (SMD) compares 2 groups of measurements: treatment versus control. The SMD was calculated for both objective and subjective ratings. Studies that employed more patients were weighted heavier against studies that employed fewer patients.

RESULTS
=======

The initial database search yielded 124 studies. Twenty-five studies were added from reference lists of reviews and filtered using the inclusion and exclusion criteria specified above.^[@R3],[@R4]^ One hundred articles were excluded following title and abstract review. Thirty-five studies were excluded following full-text screening. A total of 14 studies remained and discussed in this review (Fig. [2](#F2){ref-type="fig"}).
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A summary of the study characteristics is depicted in Table [1](#T1){ref-type="table"}. Fourteen studies met the inclusion criteria of attempting to treat postsurgical scars with lasers and assessed the quality of scar healing with a final scar assessment score.^[@R5]--[@R18]^ Nine studies used split scars, 2 used controlled cohorts, 1 used a split body (breasts) comparison, and 2 were prospective pilot studies. A total of 271 scars were treated with 247 matched control scars. The number of patients per study group ranged from 5 to 40 (mean = 18.5). Pulsed dye lasers (PDL), carbon dioxide (CO~2~) lasers, and diode lasers were the most commonly used devices followed by erbium glass (Er-Glass) and potassium titanyl phosphate (KTP) lasers.

###### 

Study Characteristics

  Article                          Device     Type of Control   No. Patients   Objective Scale   
  -------------------------------- ---------- ----------------- -------------- ----------------- ------------
  Nouri et al^[@R5]^               PDL        Split scar        12             ---               VSS
  Alam et al^[@R6]^                PDL        Split scar        17             ---               1--4 scale
  Conologue and Norwood^[@R7]^     PDL        Split scar        13             ---               VSS
  Capon et al^[@R8]^               Diode      Split scar        5              ---               1--4 scale
  Choe et al^[@R9]^                Er-glass   Separate group    27             14                VSS
  Capon et al^[@R10]^              Diode      Split scar        30             ---               0--3 scale
  Carvalho et al^[@R11]^           Diode      Separate group    14             14                VSS
  Yun et al^[@R12]^                KTP        Separate group    20             8                 VSS
  Lee et al^[@R13]^                CO~2~      Split scar        15             ---               VSS
  Sobanko et al^[@R14]^            CO~2~      Split scar        20             ---               VSS
  Vazquez-Martinez et al^[@R15]^   PDL        Split scar        30             ---               VSS
  Buelens et al^[@R16]^            CO~2~      Split scar        9              ---               GAS, POSAS
  Alberti et al^[@R17]^            CO~2~      Separate group    20             21                VSS
  Casanova et al^[@R18]^           Diode      Split chest       40             ---               mOSAS

In split scar studies, the number of treated patients equals the number of controls.

GAS, Global Assessment Scale; mOSAS, modified Observer Scar Assessment Scale; POSAS, Patient Observer Scar Assessment Scale.

Various protocols were employed; laser treatments were performed 2--10 times at 2- to 10-week intervals. Most study protocols included 3--4 treatments at intervals of 2--4 weeks. For all but one study,^[@R16]^ the first laser treatment was scheduled after suture removal.

The VSS was used in 8 of the 15 studies. Most of the studies used multiple scales for each objective (physician) and subjective (patient) evaluations of the outcomes of scars. The objective SMD between treatment and control for all cumulative studies was calculated to be 0.777 (95% CI, 0.368--1.186). Statistically significant differences were measured between treated and untreated scars among physicians and patients.

Diode lasers treatment lead to the greatest SMD of 0.624 (95% CI, 0.322--0.925) and CO~2~ the lowest overall SMD with 0.43 (95% CI, 0.0794--0.780). The SMD for KTP, 2.669 (95% CI, 1.558--3.779), and Er-glass lasers, 0.876 (95% CI, 0.194--1.557), had the best results compared with controls, however, with low weights and a wide CIs. Objectively, the SMD of PDL, 0.45 (95% CI, 0.116--0.784), was similar to that of CO~2~. These results are shown in Figure [3](#F3){ref-type="fig"}.

![Graphical depictions of standardized mean differences between treatment and controls among (A) objective results achieved by the studies, (B) objective results achieved by specific devices, and (C) subjective results achieved by specific devices. The box size of each data point depicts the weight of the device, which was deemed dependent on the number of patients treated. The whiskers of each box depict the standard error and thus the 95% CI.](gox-8-e2746-g003){#F3}

Patients' evaluations reflected the same results, as shown in Figure [3](#F3){ref-type="fig"}C. The SMD for diode lasers was 0.844 (95% CI, 0.275--1.413). KTP lasers reflected an SMD of 1.868 (95% CI, 0.88--2.848) in a few patients. CO~2~, with an SMD of 0.353, had statistically insignificant results among patients (95% CI, −0.483 to 1.189).

DISCUSSION
==========

Postsurgical scars are ideally flat, narrow, pale, and pliable. Abnormal scars may range from hypertrophic to keloid. Abnormal scars can be unsightly, painful, functionally, and socially limiting. Various scar mitigation options exist.^[@R19]^ This study provides a systematic review of trials performed over the last 2 decades that investigate mitigation of postoperative scars using a variety of single laser modalities and treatment protocols.

Four studies out of 14 did not demonstrate statistical significance with the treatment of postsurgical scars. Alam et al^[@R6]^ employed a single PDL treatment immediately postsurgery and concluded that more treatments are necessary to achieve a therapeutic effect. Buelens et al^[@R16]^ and Sobanko et al^[@R14]^ failed to show statistically significant improvement using fractional CO~2~ laser monotherapy. However, higher patient satisfaction was statistically significant for treated scars.^[@R16]^

Statistically, significant scar improvement was found in the remaining 10 studies. Diode, PDL, and CO~2~ lasers were reported to have the best results compared with controls. Although the exact mechanics are not entirely understood, diode lasers have been shown to increase heat-shock-protein 70 induction, which is known to induce collagen proliferation and modulate transforming growth factor beta (TGF-β) expression, and remodeling.^[@R8],[@R20],[@R21]^

PDL and KTP lasers best target the oxy- and deoxyhemoglobin chromophores and are best utilized to alleviate the erythema associated with highly vascular postsurgical scars.^[@R22]--[@R25]^ Also, PDL has been shown to upregulate p53, inhibiting cell proliferation, and reducing angiogenesis that contributes to abnormal scarring.^[@R26]^ Optimal results were achieved after 3 PDL treatments.^[@R5]--[@R7],[@R15]^ Treatment intervals ranged from 2 to 10 weeks. All 4 studies started treatment on the day of suture removal and proved to be safe and efficacious.^[@R5],[@R27]^

Both KTP and PDL lasers exhibited substantial improvement in similar categories of scar treatment; however, neither have had statistically significant results when compared with the other.^[@R28]^ KTP lasers have been associated with more posttreatment pain, erythema, and edema.^[@R28],[@R29]^

The chromophore targeted by CO~2~ lasers is water, found in tissues. CO~2~ laser treatments are considered more aggressive and lead to considerable dermal matrix remodeling, hopefully leading to favorable remodeling of the scar.^[@R25],[@R30]^ Half of the studies exploring the treatment of postsurgical scars using only CO~2~ lasers reported statistically insignificant results with a collectively low SMD.

Combining different modalities may augment scar mitigation. A synergistic effect can be achieved from combining PDL treatment, targeting scar vascularity and pigmentation, followed by fractional CO~2~, and aimed at improving the texture, pliability, and height of the scar.^[@R31]--[@R33]^ Also, combination of laser treatment with triamcinolone injection has shown promising results, perhaps by inhibiting fibroblasts and TGF-β.^[@R25],[@R31],[@R34]--[@R36]^ Combining Er:yttrium aluminum garnet (YAG) fractional ablation after PDL treatment improved scar pliability in addition to scar appearance.^[@R37]^

Our review is inherently limited by its attempt to compare different studies using various measurement scales and patient populations. This made it difficult to compare among protocols, devices, and parameters. Also, aside from 2 listed patients in one study,^[@R7]^ only patients less prone to hypertrophic or keloid scarring are evaluated. Future studies should explore high-risk patients such as patients with abnormal scarring history or patients undergoing midline or limb incisions. Moreover, standardized objective measuring tools such as 3D, infrared cameras, and standard scar scales should be encouraged.

CONCLUSIONS
===========

Laser therapy is a safe and effective modality for scar mitigation. The data suggest that early intervention exhibits the best results. We recommended beginning treatment close to suture removal combining vascular and nonablative fractional resurfacing modalities for 2--4 treatments at 2- to 3-week intervals. It is imperative to monitor the wound healing process and document side effects such as erythema, discoloration, pain, and infection. Further research may help define standard treatment protocols which would benefit both evaluations of the results and clinical outcome.
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